Magle Chemoswed Holding AB (publ) (OM:MAGLE) signed a binding term sheet to acquire Pk Biotech Aps from Prs1 Aps for SEK 240 million on June 17, 2024. The consideration consists of 7.2 million common equity of Magle Chemoswed Holding AB (publ). The consideration shares will be subject to a one-year lock-up undertaking for the seller and certain ultimate owners of the seller.

Along with pK Biotech ApS, its subsidiary pK Chemicals A/S, will also be acquired by Magle Chemoswed Holding AB (publ) (OM:MAGLE). Magle Group's Board of Directors will convene a shareholders' meeting to resolve on the new issue of the consideration shares, resulting in a dilution of 40 percent based on the current number of shares and votes in Magle Group. The transaction is subject to the parties entering into a merger agreement, due diligence, regulatory approvals, and a shareholders' meeting in Magle Group to approve the new issue of shares.

Vator Securities acted as financial advisor and Advokatfirman Schjødt acted as legal advisor for Magle Chemoswed Holding AB.